{"organizations": [], "uuid": "c6334eacd64a33a1c9da9b8eddc6c9bcf4edec7c", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180206.html", "section_title": "Archive News &amp; Video for Tuesday, 06 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-actinium-pharmaceuticals-announces/brief-actinium-pharmaceuticals-announces-trial-to-study-actimab-a-in-combination-with-clag-m-idUSFWN1PW0PO", "country": "US", "domain_rank": 408, "title": "BRIEF-Actinium Pharmaceuticals Announces Trial To Study Actimab-A In Combination With CLAG-M", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.425, "site_type": "news", "published": "2018-02-06T20:38:00.000+02:00", "replies_count": 0, "uuid": "c6334eacd64a33a1c9da9b8eddc6c9bcf4edec7c"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-actinium-pharmaceuticals-announces/brief-actinium-pharmaceuticals-announces-trial-to-study-actimab-a-in-combination-with-clag-m-idUSFWN1PW0PO", "ord_in_thread": 0, "title": "BRIEF-Actinium Pharmaceuticals Announces Trial To Study Actimab-A In Combination With CLAG-M", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters) - actinium pharmaceuticals inc", "sentiment": "neutral"}, {"name": "aml", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 6 (Reuters) - Actinium Pharmaceuticals Inc:\n* ACTINIUM PHARMACEUTICALS ANNOUNCES TRIAL TO STUDY ACTIMAB-A IN COMBINATION WITH CLAG-M FOR RELAPSED OR REFRACTORY AML PATIENTS\n* ACTINIUM PHARMA - COMBINATION ALIGNS WITH ACTINIUMâ€˜S FOCUS ON IMPROVING BONE MARROW TRANSPLANT ACCESS AND OUTCOMES THROUGH IMPROVED MYELOABLATION Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-06T20:38:00.000+02:00", "crawled": "2018-02-07T22:23:34.000+02:00", "highlightTitle": ""}